Halozyme Therapeutics, Inc. (NASDAQ:HALO) was the target of some unusual options trading activity on Thursday. Stock traders acquired 1,796 put options on the company. This is an increase of approximately Infinity compared to the average daily volume of 0 put options.

Shares of Halozyme Therapeutics (HALO) opened at $18.18 on Friday. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.46 and a quick ratio of 3.94. Halozyme Therapeutics has a 12 month low of $9.68 and a 12 month high of $19.37.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.04). The company had revenue of $63.73 million for the quarter, compared to analyst estimates of $58.95 million. Halozyme Therapeutics had a negative return on equity of 892.57% and a negative net margin of 53.17%. The business’s quarterly revenue was up 100.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.23) EPS. analysts expect that Halozyme Therapeutics will post 0.09 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Trexquant Investment LP acquired a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth about $224,000. JPMorgan Chase & Co. lifted its stake in shares of Halozyme Therapeutics by 7.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,868,670 shares of the biopharmaceutical company’s stock worth $49,915,000 after buying an additional 191,476 shares during the last quarter. Legal & General Group Plc lifted its stake in shares of Halozyme Therapeutics by 36.4% during the 3rd quarter. Legal & General Group Plc now owns 60,157 shares of the biopharmaceutical company’s stock worth $1,045,000 after buying an additional 16,041 shares during the last quarter. Great West Life Assurance Co. Can lifted its stake in shares of Halozyme Therapeutics by 44.1% during the 3rd quarter. Great West Life Assurance Co. Can now owns 14,291 shares of the biopharmaceutical company’s stock worth $248,000 after buying an additional 4,371 shares during the last quarter. Finally, American International Group Inc. lifted its stake in shares of Halozyme Therapeutics by 17.0% during the 3rd quarter. American International Group Inc. now owns 79,210 shares of the biopharmaceutical company’s stock worth $1,376,000 after buying an additional 11,482 shares during the last quarter. Institutional investors own 85.24% of the company’s stock.

A number of research firms recently weighed in on HALO. Canaccord Genuity raised their target price on shares of Halozyme Therapeutics from $17.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday. BMO Capital Markets raised their target price on shares of Halozyme Therapeutics from $15.00 to $18.00 and gave the company a “market perform” rating in a research report on Wednesday. Piper Jaffray Companies raised their target price on shares of Halozyme Therapeutics from $26.00 to $29.00 and gave the company an “overweight” rating in a research report on Monday, October 16th. Zacks Investment Research downgraded shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, October 6th. Finally, Deutsche Bank AG raised their target price on shares of Halozyme Therapeutics to $20.00 and gave the company a “buy” rating in a research report on Friday, September 15th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company. Halozyme Therapeutics has a consensus rating of “Hold” and an average price target of $17.75.

COPYRIGHT VIOLATION WARNING: “Investors Purchase High Volume of Put Options on Halozyme Therapeutics (HALO)” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.thecerbatgem.com/2017/11/12/investors-purchase-high-volume-of-put-options-on-halozyme-therapeutics-halo.html.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Receive News & Stock Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related stocks with our FREE daily email newsletter.